Cargando…
PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis
BACKGROUND: The Mycobacterium tuberculosis (M.tb) protein kinase B (PknB) which is now proved to be essential for the growth and survival of M.tb, is a transmembrane protein with a potential to be a good drug target. However it is not known if this target remains conserved in otherwise resistant iso...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562987/ https://www.ncbi.nlm.nih.gov/pubmed/28821299 http://dx.doi.org/10.1186/s12941-017-0234-9 |
_version_ | 1783258049858764800 |
---|---|
author | Gupta, Anamika Pal, Sudhir K. Pandey, Divya Fakir, Najneen A. Rathod, Sunita Sinha, Dhiraj SivaKumar, S. Sinha, Pallavi Periera, Mycal Balgam, Shilpa Sekar, Gomathi UmaDevi, K. R. Anupurba, Shampa Nema, Vijay |
author_facet | Gupta, Anamika Pal, Sudhir K. Pandey, Divya Fakir, Najneen A. Rathod, Sunita Sinha, Dhiraj SivaKumar, S. Sinha, Pallavi Periera, Mycal Balgam, Shilpa Sekar, Gomathi UmaDevi, K. R. Anupurba, Shampa Nema, Vijay |
author_sort | Gupta, Anamika |
collection | PubMed |
description | BACKGROUND: The Mycobacterium tuberculosis (M.tb) protein kinase B (PknB) which is now proved to be essential for the growth and survival of M.tb, is a transmembrane protein with a potential to be a good drug target. However it is not known if this target remains conserved in otherwise resistant isolates from clinical origin. The present study describes the conservation analysis of sequences covering the inhibitor binding domain of PknB to assess if it remains conserved in susceptible and resistant clinical strains of mycobacteria picked from three different geographical areas of India. METHODS: A total of 116 isolates from North, South and West India were used in the study with a variable profile of their susceptibilities towards streptomycin, isoniazid, rifampicin, ethambutol and ofloxacin. Isolates were also spoligotyped in order to find if the conservation pattern of pknB gene remain consistent or differ with different spoligotypes. The impact of variation as found in the study was analyzed using Molecular dynamics simulations. RESULTS: The sequencing results with 115/116 isolates revealed the conserved nature of pknB sequences irrespective of their susceptibility status and spoligotypes. The only variation found was in one strains wherein pnkB sequence had G to A mutation at 664 position translating into a change of amino acid, Valine to Isoleucine. After analyzing the impact of this sequence variation using Molecular dynamics simulations, it was observed that the variation is causing no significant change in protein structure or the inhibitor binding. CONCLUSIONS: Hence, the study endorses that PknB is an ideal target for drug development and there is no pre-existing or induced resistance with respect to the sequences involved in inhibitor binding. Also if the mutation that we are reporting for the first time is found again in subsequent work, it should be checked with phenotypic profile before drawing the conclusion that it would affect the activity in any way. Bioinformatics analysis in our study says that it has no significant effect on the binding and hence the activity of the protein. |
format | Online Article Text |
id | pubmed-5562987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55629872017-08-21 PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis Gupta, Anamika Pal, Sudhir K. Pandey, Divya Fakir, Najneen A. Rathod, Sunita Sinha, Dhiraj SivaKumar, S. Sinha, Pallavi Periera, Mycal Balgam, Shilpa Sekar, Gomathi UmaDevi, K. R. Anupurba, Shampa Nema, Vijay Ann Clin Microbiol Antimicrob Research BACKGROUND: The Mycobacterium tuberculosis (M.tb) protein kinase B (PknB) which is now proved to be essential for the growth and survival of M.tb, is a transmembrane protein with a potential to be a good drug target. However it is not known if this target remains conserved in otherwise resistant isolates from clinical origin. The present study describes the conservation analysis of sequences covering the inhibitor binding domain of PknB to assess if it remains conserved in susceptible and resistant clinical strains of mycobacteria picked from three different geographical areas of India. METHODS: A total of 116 isolates from North, South and West India were used in the study with a variable profile of their susceptibilities towards streptomycin, isoniazid, rifampicin, ethambutol and ofloxacin. Isolates were also spoligotyped in order to find if the conservation pattern of pknB gene remain consistent or differ with different spoligotypes. The impact of variation as found in the study was analyzed using Molecular dynamics simulations. RESULTS: The sequencing results with 115/116 isolates revealed the conserved nature of pknB sequences irrespective of their susceptibility status and spoligotypes. The only variation found was in one strains wherein pnkB sequence had G to A mutation at 664 position translating into a change of amino acid, Valine to Isoleucine. After analyzing the impact of this sequence variation using Molecular dynamics simulations, it was observed that the variation is causing no significant change in protein structure or the inhibitor binding. CONCLUSIONS: Hence, the study endorses that PknB is an ideal target for drug development and there is no pre-existing or induced resistance with respect to the sequences involved in inhibitor binding. Also if the mutation that we are reporting for the first time is found again in subsequent work, it should be checked with phenotypic profile before drawing the conclusion that it would affect the activity in any way. Bioinformatics analysis in our study says that it has no significant effect on the binding and hence the activity of the protein. BioMed Central 2017-08-18 /pmc/articles/PMC5562987/ /pubmed/28821299 http://dx.doi.org/10.1186/s12941-017-0234-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gupta, Anamika Pal, Sudhir K. Pandey, Divya Fakir, Najneen A. Rathod, Sunita Sinha, Dhiraj SivaKumar, S. Sinha, Pallavi Periera, Mycal Balgam, Shilpa Sekar, Gomathi UmaDevi, K. R. Anupurba, Shampa Nema, Vijay PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis |
title | PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis |
title_full | PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis |
title_fullStr | PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis |
title_full_unstemmed | PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis |
title_short | PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis |
title_sort | pknb remains an essential and a conserved target for drug development in susceptible and mdr strains of m. tuberculosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562987/ https://www.ncbi.nlm.nih.gov/pubmed/28821299 http://dx.doi.org/10.1186/s12941-017-0234-9 |
work_keys_str_mv | AT guptaanamika pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT palsudhirk pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT pandeydivya pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT fakirnajneena pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT rathodsunita pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT sinhadhiraj pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT sivakumars pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT sinhapallavi pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT perieramycal pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT balgamshilpa pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT sekargomathi pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT umadevikr pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT anupurbashampa pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis AT nemavijay pknbremainsanessentialandaconservedtargetfordrugdevelopmentinsusceptibleandmdrstrainsofmtuberculosis |